Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3353-3362

  Gulley, James L ^a   Arlen, Philip M ^a   Bastian, Anne ^a   Morin, Steven ^a   Marte, Jennifer ^a   Beetham, Patricia ^a   Tsang, Kwong Yok ^a   Yokokawa, Junko ^a   Hodge, James W ^a   Ménard, Cynthia ^a   Camphausen, Kevin ^a   Coleman, C Norman ^a   Sullivan, Francis ^b   Steinberg, Seth M ^a   Schlom, Jeffrey ^a   Dahut, William ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Maryland Regional Cancer Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN; VACCINIA VACCINE;

ADULT; AGED; ANOREXIA; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL KILLING; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DYSPNEA; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; LUNG TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUMOR LOCALIZATION; VACCINATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD80; CANCER VACCINES; CELL LINE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 20944441967     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2062     Document Type: Article

References (56)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Dillioglugil O, Leibman BD, Kattan MW, SealeHawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997; 50:93-9.
3. Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000;163:1155-60.
4. 0 prostatic adenocarcinoma-long-term results. J Urol 1990;144: 1180-4.
5. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-8.
6. Pilepich MV, Winter K, Lawton C, et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 2003;22:A1530.
7. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8.
8. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res 1995;55:3598-603.
9. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-94.
10. Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300.
11. Hodge JW Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995;63: 231-7.
12. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53: 109-17.
13. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6:1632-8.
14. Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999;53: 260-6.
15. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15: 759-68.
16. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22: 2122-32.
17. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant non-replicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73.
18. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170: 6338-47.
19. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-80.
20. Garnett CT, Palena C, Chakarborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94.
21. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64: 4328-37.
22. Belka C, Ottinger H, Kreuzfelder E, et al. Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol 1999;50: 199-204.
23. Tisch M, Heimlich F, Daniel V, Opelz G, Maier H. Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer. Otolaryngol Head Neck Surg 1998;119: 412-7.
24. Cox JD, Grignon DJ, Kaplan RS, et al. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37: 1035-41.
25. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1996;93:10972-7.
26. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17: 332-7.
27. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62: 5770-7.
28. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411: 380-4.
29. Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anti-cancer vaccines. Cancer J Sci Am 2000;6 Suppl 1: S76-80.
30. Arlen P, Tsang KY, Marshall JL, et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000;49:517-29.
31. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003; 9:1837-49.
32. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-14.
33. Boyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. Scand J Clin Lab Invest Suppl 1968;97:51-76.
34. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J Exp Med 1994;179:1109-18.
35. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
36. Bunn PA, Weiss GR, Hicks WJ, Gandara DR, Rivkin S. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung-cancer-a prospective phase-III randomized study of the Southwest-Oncology-Group. J Clin Oncol 1995;13:1632. Erratum in: J Clin Oncol 1995; 13:2860.
37. Bunn PA, Weiss GR, Hicks WJ, Gandara DR, Rivkin S. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung-cancer-a prospective phase-III randomized study of the Southwest-Oncology-Group. J Clin Oncol 1995;13:1632. Erratum in: J Clin Oncol 1995; 13:2860.
38. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
39. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 2004;10:2139-49.
40. Verastegui EL, Morales RB, Barrera-Franco JL, Poitevin AC, Hadden J. Long-term immune dysfunction after radiotherapy to the head and neck area. Int Immunopharmacol 2003;3:1093-104.
41. +) T-cells and decrease of naive (Cd4-Cd45R) lymphocytes-T. Eur J Cancer 1992;28A:1729-34.
42. Musabak U, Bolu E, Ozata M, et al. Gonadotropin treatment restores in vitro interleukin-1β and tumour necrosis factor-α production by stimulated peripheral blood mononuclear cells from patients with idiopathic hypogonadotropic hypogonadism. Clin Exp Immunol 2003;132:265-70.
43. Castagnetta L, Granata OM, Traina A, et al. A role for sex steroids in autoimmune diseases-a working hypothesis and supporting data. Ann N Y Acad Sci 2002;966:193-203.
44. Cutolo M, Sulli A, Capellino S, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004;13:635-8.
45. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996;17:369-84.
46. Benten WP, Lieberherr M, Giese G, et al. Functional testosterone receptors in plasma membranes of T cells. FASEB J 1999;13:123-33.
47. Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Neuroendocrine immune basis of the rheumatic diseases. II. Proceedings of the second international conference. Ann N Y Acad Sci 2002;966:131-42.
48. Yao GH, Liang J, Han XD, Hou YY. In vivo modulation of the circulating lymphocyte subsets and monocytes by androgen. Int Immunopharmacol 2003;3:1853-60.
49. Kocar Ih, Yesilova Z, Ozata M, Turan M, Sengul A, Ozdemir I. The effect of testosterone replacement treatment on immunological features of patients with Klinefelter's syndrome. Clin Exp Immunol 2000;121: 448-52.
50. Arlen P, Gulley J, Novik L, et al. A randomized phase II trial of either vaccine therapy (recombinant pox viruses expressing PSA and the B7.1 costimulatory molecule) versus hormone therapy (nilutamide) in patients with hormone refractory prostate cancer and no radiographic evidence of disease. J Urol 2003 May 1;169:243.
51. Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 2003;97:186-200.
52. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
53. Kudo-Saito C, Schlom J, Hodge JW. Intratumoral vaccination and diversified subcutaneous/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin Cancer Res 2004;10:1090-9.
54. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993;151:3693-703.
55. Klyushnenkova EN, Ponniah S, Rodriguez A, et al. CD4 and CD8T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother 2004;27:136-46.
56. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565-70.